Last A$0.08 AUD
Change Today +0.001 / 1.27%
Volume 83.2K
As of 9:43 PM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).

phosphagenics ltd (POH) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/28/14 - A$0.12
52 Week Low
11/27/14 - A$0.06
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for PHOSPHAGENICS LTD (POH)

Related News

No related news articles were found.

phosphagenics ltd (POH) Related Businessweek News

No Related Businessweek News Found

phosphagenics ltd (POH) Details

Phosphagenics Limited, a biotechnology company, produces, sells, and licenses products for the pharmaceutical, cosmetics, and animal health industries. It is involved in the commercialization of drug delivery applications based on its transdermal Targeted Penetration Matrix (TPM) technology that is used to deliver pharmaceutical and nutraceutical products. Its Skin Care segment provides a range of products to enhance the appearance of skin. The company’s Pain Portfolio segment focuses on enhancing the delivery of opioids used for pain treatment through the skin. Phosphagenics Limited serves various customers in Australia, Germany, Switzerland, and the United States. The company was formerly known as Vital Capital Limited and changed its name to Phosphagenics Limited in 2004. Phosphagenics Limited is headquartered in Clayton, Australia.

35 Employees
Last Reported Date: 02/28/14

phosphagenics ltd (POH) Top Compensated Officers

Founder, President, Executive Director and Me...
Total Annual Compensation: A$412.6K
Chief Financial Officer
Total Annual Compensation: A$145.2K
General Counsel
Total Annual Compensation: A$204.2K
General Manager of Personal Care
Total Annual Compensation: A$151.0K
Chief Scientific Officer
Total Annual Compensation: A$167.6K
Compensation as of Fiscal Year 2013.

phosphagenics ltd (POH) Key Developments

Phosphagenics Seeks A Partnership With Pharmaceutical Firms

Phosphagenics Limited (ASX:POH) is seeking for a partnership with pharmaceutical giants and consider simplifying the company's many and varied projects.

Phosphagenics Appoints Ross Murdoch as CEO

Phosphagenics Limited announced the appointment of Dr. Ross Murdoch as CEO. Dr. Murdoch has more than 25 years of experience leading and managing the strategic, scientific and operational aspects of product research, development and commercialization across the healthcare, biotechnology and pharmaceutical Industries. Dr. Ross Murdoch has acted in many senior roles in both the biotechnology and pharmaceutical industries, including in more recent times the following: Senior Vice President at Shire Pharmaceuticals, responsible for founding and building the Emerging Products Business and the Hematology Business, as well as managing the move of the Specialty Pharmaceutical Business to Switzerland; President and COO of Prana Biotechnology Limited (Australia) where he played a key role in a number of capital raisings and Prana’s NASDAQ listing. Dr. Murdoch is relocating from the USA to Melbourne to take up this role. The appointment is on an ongoing basis and commences with effect from 12 January 2015.

Phosphagenics Limited Reports Audited Consolidated Earnings Results for the Six Months Ended June 30, 2014

Phosphagenics Limited reported audited consolidated earnings results for the six months ended June 30, 2014. For the period, the company reported total revenue of AUD 712,000 against AUD 929,000 a year ago. Loss before income tax was AUD 2,785,000 against AUD 6,072,000 a year ago. Loss after income tax was AUD 2,785,000 or 0.27 cents per basic and diluted share against AUD 6,072,000 or 0.59 cents per basic and diluted share a year ago. Net cash out flow from operating activities was AUD 1,170,000 against AUD 2,820,000 a year ago. Purchase of plant and equipment was AUD 13,000 against AUD 31,000 a year ago. A net tangible asset per security was 1.18 cents against 1.69 cents a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
POH:AU A$0.08 AUD +0.001

POH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Durect Corp $0.94 USD +0.03
View Industry Companies

Industry Analysis


Industry Average

Valuation POH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 42.4x
Price/Book 1.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 47.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHOSPHAGENICS LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at